As controversy over childhood deaths simmers in the Philippines, Sanofi balks at a Dengvaxia reimbursement
Sanofi is in the middle of a heated controversy in the Philippines that shows no signs of dying out anytime soon.
Over the last few days the pharma giant has had to reject calls for reimbursing the government for the cost of hundreds of thousands of doses of Dengvaxia. And public health officials raised a ruckus by pointing to several deaths among children which they say could have been triggered by the vaccine. In the meantime there are signs that the panic over Dengvaxia has raised fears about all such jabs, leading to a sharp drop in badly needed vaccinations.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
